Literature DB >> 7551372

Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone.

I Azevedo1, J de Blic, P Scheinmann, B B Vargaftig, M Bachelet.   

Abstract

To test the hypothesis that alveolar macrophages (AM) from wheezy infants release increased amounts of eicosanoids, as do AM from adults with asthma, we compared eicosanoid release by unstimulated- and ionophore-A23187-stimulated AM from 13 wheezy and six nonwheezy infants and analyzed its regulation by dexamethasone in vitro. Alveolar macrophages from wheezy infants released greater amounts of thromboxane A2 (TxA2) and leukotriene B4 (LTB4) under resting conditions and of TxA2 upon stimulation than did those from control subjects. Dexamethasone induced a dose-dependent inhibition of the spontaneous and A23187-stimulated release of TxA2, but not of the A23187-stimulated release of lipoxygenase products. The inhibition of TxA2 formation was maintained when free arachidonic acid was added during A23187 stimulation, demonstrating that dexamethasone acted mainly at a postphospholipase A2 site. AM exposed to acetylsalicylate and then incubated overnight exhibited de novo cyclooxygenase synthesis, suggesting the presence of the inducible cyclooxygenase as a target for inhibition by dexamethasone. In conclusion, our findings suggest that AM from wheezy infants are activated in vivo to release eicosanoids, as are AM from asthmatic adults, and they support the therapeutic indications of glucocorticoids in severe recurrent wheezing of infancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551372     DOI: 10.1164/ajrccm.152.4.7551372

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  4 in total

Review 1.  The role of inflammation in childhood asthma.

Authors:  F Chedevergne; M Le Bourgeois; J de Blic; P Scheinmann
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

2.  Lower arrythmogenic risk of low dose albuterol plus ipratropium.

Authors:  H Yuksel; S Coskun; M Polat; A Onag
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

3.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

Review 4.  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.

Authors:  Richard B R Muijsers; Stuart Noble
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.